medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2014, Number 07

<< Back Next >>

Ginecol Obstet Mex 2014; 82 (07)

Safety and effectiveness of oral hypoglycemic agents in women with gestational diabetes. Literature Review

Buitrago-Leal M, Molina-Giraldo S

Language: Spanish
References: 24
Page: 454-464
PDF size: 399.67 Kb.


ABSTRACT

Background: The aim of this article is to review the estimates of studies have proposed the use of oral hypoglycemic agents (HGO) for metabolic 455 Buitrago-Leal M y Molina-Giraldo S. Seguridad y efectividad de los hipoglucemiantes orales control in patients with Gestational Diabetes Mellitus (GDM ), evaluating outcomes regarding effectiveness and safety : breast, fetal, obstetric and neonatal outcome; comparing these outcomes with insulin therapy and among themselves, in order to contribute to understand the risks and benefits of using HGO in the current management of GDM.
Materials and methods: A review was carried out in the literature recorded in four databases: PubMed , Ovid , Cochrane and ProQuest, between December 2007 and December 2012.
Results: Clinical trials (n = 7) , meta-analysis (n = 2) , systematic reviews (n = 2) , cohort studies : (n = 3), cost analysis study (n = 1) and ranked 15 items were included.
Conclusion: HGO provide adequate control of maternal glycemia and perinatal results comparable insulin therapy, and they should be considered as effective and safe option in the treatment of GDM.


REFERENCES

  1. Castorino K, Jovanovic L. Pregnancy and Diabetes Management: Advances and Controversies. Clinical Chemistry 2011;57:221-230.

  2. Renda E, Faraci M, DiPrima FAF, Valenti O, Hiseni E, Monte S, Giorgio E, De Domenico R. Treatment of gestational diabetes: oral hypoglycemic agents or insulin? Journal of Prenatal Medicine 2011;5:63-64.

  3. Valdés E, Soto-Chacón E, Lahsen R, Barrera C, Candia P. Eficacia de los hipoglucemiantes orales en el control metabólico de pacientes con diabetes mellitus gestacional. Rev Med Chile 2008;136:915-920.

  4. Magon N, Seshiah V. Gestational diabetes mellitus: Noninsulin management. Indian Journal of Endocrinology and Metabolism 2011;15:284-293.

  5. Robed A, Mohammad ZH, Titu M, Rubina Y, Faizul IC, Aminul H. Are oral hypoglycemic agents contraindicated in Pregnancy. J Bangladesh Coll Phys Surg 2010;28:129-131.

  6. Gutzin SJ, Kozer E, Magee LA, Feig DS, Koren G. The safety of oral hypoglicemic agent in the first trimester of pregnancy: A meta-analysis. Can J Clin Pharmacol 2003;10:179-183.

  7. Langer O, Conway D, Berkus M, Xenakis E, Gonzalez O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343:1134-38.

  8. Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol 2010:203:457.e1-9.

  9. Moretti ME, Rezvani M, KorenG. Safety of Glyburide for gestational diabetes: A meta-analysis of pregnancy outcomes. Ann Pharmacother 2008;42:483-90.

  10. Nicholson W, Bolen S, Witkop C, Neale D, Wilson L, Bass E. Benefits and Risks of Oral Diabetes Agents Compared with Insulin in Women with Gestational Diabetes. A Systematic Review. Obstet Gynecol 2009; 113:193-205.

  11. Rowan JA, Hague WM, Moore MP. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003-15.

  12. Feig D, Moses R. Metformin. Therapy during pregnancy. Diabetes Care 2011;34:2329-30.

  13. Moore LE, Briery CM, Clokey D, et al. Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. J Reprod Med 2007;52:1011-1015.

  14. Cheng IW, Chung JH, Block-Kurvisch I, Inturrisi M, Caughey AB. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. J Matern Fetal Neonatal Med 2012;25:379-384.

  15. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Human Reproduction 2004;19:1323-1330.

  16. Goetzl L, Wilkins I. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. Journal of Perinatology 2002;22:403-406.

  17. Chmait R, Dinise T, Moore T. Prospective Observational Study to Establish Predictors of Glyburide Success in Women with Gestational Diabetes Mellitus. Journal of Perinatology 2004;24:617-622.

  18. Rochon M, Rand L, Roth L, Gaddipati S. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. Am J Obstet Gynecol 2006; 195:1090-1094.

  19. Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour LA. Predictors of Glyburide Failure in the Treatment of Gestational Diabetes. Obstet Gynecol 2006;107:1303-1309.

  20. Yogev Y, Melamed N, Chen R, Pardo J, Hod M. Glyburide in gestational diabetes -prediction of treatment failure. J Maternal-Fetal and Neonatal Medicine 2011;24:842- 846.

  21. Holt RIG, Clarke P, Parry EC, Coleman MAG. The effectiveness of glibenclamide in women with gestational diabetes. Diabetes, Obesity and Metabolism 2008;10:906-911.

  22. Mukhopadhyay P, Bag TS, Kyal A, Saha DP, Khalid N. Oral Hypoglycemic Glibenclamide: Can it be a Substitute to Insulin in the Management of Gestational Diabetes Mellitus? A Comparative Study. J Asian Fed Obstet Gynaecol 2012;4:28-31.

  23. Koren G. Glyburide and fetal safety transplacental pharmacokinetic considerations. Reprod Toxicol 2001;15:227-229.

  24. Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 2005;83:1575-1578.




2020     |     www.medigraphic.com